ReviewJournal of the Korean Society of Radiology2025
LI-RADS CT/MRI Treatment Response Assessment Update in 2024.
Review in Journal of the Korean Society of Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Magnetic resonance imaging findings after stereotactic body radiation therapy for hepatocellular carcinoma - a scoping literature review.Clinical and translational radiation oncology · 2026Review
- Review
- Irreversible electroporation vs. stereotactic body radiotherapy for solitary hepatocellular carcinoma ≤5 cm: A multicenter retrospective study.JHEP reports : innovation in hepatology · 2026Article
- LI-RADS TRA v2024 succeeds where RECIST and mRECIST fail: viability-based survival prediction in TACE-treated hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- MRI after Interventional Therapy of Hepatocellular Carcinoma: Typical Changes over Time.RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin · 2026Review
- [Preface for the Special Issue on Liver Imaging in Focus].Journal of the Korean Society of Radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver imaging reporting and data system (LI-RADS) CT/MRI treatment response assessment (TRA) provides a standardized framework for evaluating treatment response following loco-regional therapy for hepatocellular carcinoma (HCC). Initially introduced in 2017, it was revised in 2024 to reflect advances in research. The updated LI-RADS CT/MRI TRA v2024 presents a bifurcated algorithm based on the mechanisms underlying loco-regional therapy and introduces distinct assessment criteria with which to evaluate treatment response after radiation therapy. Furthermore, ancillary imaging features, including diffusion restriction and mild-to-moderate T2 hyperintensity, have been incorporated as optional adjuncts to refine the assessment of viable tumors. The effective implementation of the LI-RADS CT/MRI TRA v2024 is anticipated to enhance treatment response assessment following loco-regional therapy for HCC. Further research is encouraged in order to ensure the continuous refinement and optimization of the assessment criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.